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Commentary
Rao and associates are to be congratulated for carry-
ing out a rare feat in cardiac surgery, a prospective ran-
domized trial comparing two surgical therapeutic
options. This randomized trial of 56 patients undergo-
ing coronary bypass grafting with continuous tepid car-
dioplegia demonstrated that the addition of insulin in
the cardioplegic solution decreased initial systemic
vascular resistance, increased early cardiac output and
stroke work, decreased serum potassium levels, and
improved early cardiac lactate extraction. The authors
concluded that insulin cardioplegia improved myocar-
dial metabolic and functional recovery.
The reasons for few randomized surgical trials are
many. When cardiac function is the end point, detecting
subtle differences in cardiac function can be very diffi-
cult during concurrent changes in cardiac load. In this
study the authors were fortunate that the treatment
group had lower cardiac afterload and similar cardiac
preload, while having increased stroke work. Had after-
load increased, it might have been difficult to deter-
mine whether increased stroke work was caused by
increased contractility or by increased afterload.
Like any good study, this one raises several questions
that remain to be answered:
1. Do the beneficial effects of insulin cardioplegia in
continuous tepid cardioplegia also apply to intermittent
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cold cardioplegia? Today, intermittent cold cardiople-
gia is far more commonly used than continuous tepid
cardioplegia. The authors suggest that insulin may in
fact not be beneficial in intermittent cold cardioplegia.
Previous research looking at glucose-insulin-potassium
cardioplegia never conclusively found benefit in cold
intermittent cardioplegia. The reason may be, as the
authors suggest, that insulin may overcome a block in
mitochondrial glucose metabolism at the level of pyru-
vate dehydrogenase at warmer temperatures, although
not at colder temperatures where enzyme activities
may be markedly different. If so, the value of this study
will await greater evidence concerning the practicality
and benefits of warm tepid cardioplegia over intermit-
tent cold cardioplegia.
2. Given the relatively short 2-hour duration of bene-
fits realized from insulin cardioplegia in this study, are
these benefits great enough to be of any consequence?
Perhaps the benefit may be greater in the small number
of cases in which myocardial protection may still be
suboptimal with current techniques (ie, those with
longer ischemic times [especially cardiac transplanta-
tion] or those with poor baseline ventricular function).
The applicability of continuous tepid cardioplegia to
longer ischemic times needs to be demonstrated, given
that metabolic demands will also be greater at tepid
temperatures than at colder temperatures. Are the total
potassium loads of continuous tepid cardioplegia over
longer ischemic times adequately tolerated by patients,
particularly in patients with baseline renal insufficiency?
3. As in point 1 above, what precisely is the mecha-
nism by which insulin benefits the heart in continuous
tepid cardioplegia? The answer to this may help to clar-
ify the role of insulin in cold intermittent cardiology.
This study by Rao and associates will certainly need
to be confirmed by other investigators in other settings
before insulin can be considered a standard additive to
continuous tepid cardioplegia. In the interim, the rela-
tively clear and positive results of this study should
encourage other cardiac surgical investigators to con-
sider prospective randomized trials. Studies like this
could avoid years of heated debate in interpreting large
amounts of data that are more easily obtained but of
much lower quality.
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